Rhythm Net Income from 2010 to 2026
| RYTM Stock | USD 102.42 0.25 0.24% |
Net Loss | First Reported 2013-12-31 | Previous Quarter -46.6 M | Current Value -52.9 M | Quarterly Volatility 26.5 M |
Check Rhythm Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rhythm Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 11.9 M or Selling General Administrative of 174.2 M, as well as many indicators such as Price To Sales Ratio of 28.67, Dividend Yield of 9.0E-4 or PTB Ratio of 19.61. Rhythm financial statements analysis is a perfect complement when working with Rhythm Pharmaceuticals Valuation or Volatility modules.
Rhythm | Net Income | Build AI portfolio with Rhythm Stock |
Latest Rhythm Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Rhythm Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Rhythm Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Rhythm Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Rhythm Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rhythm Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (260.6 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Rhythm Net Income Regression Statistics
| Arithmetic Mean | (96,714,442) | |
| Coefficient Of Variation | (92.92) | |
| Mean Deviation | 79,071,226 | |
| Median | (68,007,000) | |
| Standard Deviation | 89,863,263 | |
| Sample Variance | 8075.4T | |
| Range | 254.1M | |
| R-Value | (0.91) | |
| Mean Square Error | 1488.9T | |
| R-Squared | 0.83 | |
| Slope | (16,184,702) | |
| Total Sum of Squares | 129206.5T |
Rhythm Net Income History
Other Fundumenentals of Rhythm Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Rhythm Pharmaceuticals Net Income component correlations
About Rhythm Pharmaceuticals Financial Statements
Rhythm Pharmaceuticals investors utilize fundamental indicators, such as Net Income, to predict how Rhythm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -234.5 M | -222.8 M | |
| Net Loss | -234.5 M | -222.8 M | |
| Net Loss | -163 M | -154.9 M | |
| Net Loss | (4.91) | (4.67) | |
| Net Income Per E B T | 0.90 | 0.78 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Rhythm Pharmaceuticals Correlation against competitors. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Rhythm diversify its offerings? Factors like these will boost the valuation of Rhythm Pharmaceuticals. Anticipated expansion of Rhythm directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Rhythm Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.